Key Points
- CEO Jorge Santos sold 51,873 shares on April 13 at an average of $18.23 for $945,644.79, and had earlier sold 98,127 shares on April 10 (≈$1.81M); after the transactions he still directly owns 2,924,893 shares (a 1.74% reduction) valued at about $53.32M.
- Institutional investors hold the vast majority of the stock (≈93.85%), with large buys and position increases from Cormorant, Janus Henderson, Logos and others during the latest quarter.
- Shares opened at $18.78 (up ~1.9%), MoonLake is a $1.35B market-cap clinical-stage biopharma with negative EPS (reported -$0.92 last quarter), and analysts have a mixed view — consensus rating "Hold" with a $23.08 target.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 51,873 shares of the business's stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $18.23, for a total value of $945,644.79. Following the sale, the chief executive officer directly owned 2,924,893 shares of the company's stock, valued at $53,320,799.39. This represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Da Silva Jorge Santos also recently made the following trade(s):
- On Friday, April 10th, Da Silva Jorge Santos sold 98,127 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $18.41, for a total value of $1,806,518.07.
MoonLake Immunotherapeutics Stock Up 1.9%
Shares of NASDAQ:MLTX opened at $18.78 on Wednesday. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -5.34 and a beta of 1.19. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24. MoonLake Immunotherapeutics has a 12-month low of $5.95 and a 12-month high of $62.75. The business's 50 day moving average is $17.29 and its 200 day moving average is $14.30.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.92) EPS for the quarter, meeting analysts' consensus estimates of ($0.92). During the same period in the previous year, the business earned ($0.72) earnings per share. On average, sell-side analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.
Institutional Trading of MoonLake Immunotherapeutics
A number of large investors have recently bought and sold shares of the company. Cormorant Asset Management LP increased its position in MoonLake Immunotherapeutics by 118.4% in the fourth quarter. Cormorant Asset Management LP now owns 4,355,433 shares of the company's stock worth $57,405,000 after buying an additional 2,361,260 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of MoonLake Immunotherapeutics by 18,782.8% during the 4th quarter. Janus Henderson Group PLC now owns 2,095,988 shares of the company's stock worth $27,657,000 after acquiring an additional 2,084,888 shares during the period. Logos Global Management LP bought a new position in shares of MoonLake Immunotherapeutics during the 4th quarter worth $23,065,000. Alliancebernstein L.P. increased its holdings in MoonLake Immunotherapeutics by 17.8% in the 2nd quarter. Alliancebernstein L.P. now owns 1,138,022 shares of the company's stock worth $53,715,000 after acquiring an additional 171,932 shares during the last quarter. Finally, Vivo Capital LLC purchased a new stake in MoonLake Immunotherapeutics in the 4th quarter worth about $13,180,000. 93.85% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several analysts have recently commented on MLTX shares. Rothschild & Co Redburn upgraded shares of MoonLake Immunotherapeutics from a "neutral" rating to a "buy" rating and increased their target price for the company from $12.00 to $40.00 in a report on Thursday, March 19th. BTIG Research reaffirmed a "buy" rating and issued a $30.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Monday, March 30th. The Goldman Sachs Group lowered shares of MoonLake Immunotherapeutics from a "neutral" rating to a "sell" rating and increased their price objective for the company from $8.00 to $10.00 in a research note on Wednesday, January 14th. HC Wainwright lifted their target price on shares of MoonLake Immunotherapeutics from $32.00 to $40.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Finally, Oppenheimer upped their target price on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a report on Tuesday, February 24th. Nine investment analysts have rated the stock with a Buy rating, four have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, MoonLake Immunotherapeutics currently has an average rating of "Hold" and a consensus target price of $23.08.
Check Out Our Latest Report on MoonLake Immunotherapeutics
About MoonLake Immunotherapeutics
(
Get Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
